Mindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its Drugs to Differentiate Between Their Psychedelic and Non-Psychedelic Effects

Mindset Pharma (MSET) developed a new test that eliminates one of the biggest challenges of developing a new psychedelic drug.

It can difficult to determine whether or not animals perceive a psychedelic experience when testing a new drug, but human trials are much more expensive. Mindset’s test offers a new solution.

By training rats to discriminate psilocybin from saline, Mindset developed a test that allows rats to communicate whether or not they perceive a new drug to be similar to psilocybin, which will help the company select its lead compounds for human clinical trials.

The company also announced that its psilocybin-inspired compound, MSP-1014, will target treatment resistant depression and end of life cancer angst.